From NASDAQ Stock Market: 2024-03-29 17:43:13

Summit Therapeutics saw a 23% increase in share price after positive news and analyst coverage. Stifel analyst Brad Canino predicts a near 100% upside potential with a price target of $8 per share. The company reported promising results for its lung cancer drug ivonescimab during phase 2 trials. Investors are hopeful for success in phase 3 trials. The Motley Fool Stock Advisor team did not include Summit Therapeutics in their list of top 10 stocks to buy. Before investing, consider the long and difficult road to regulatory approval for new drugs like ivonescimab.



Read more at NASDAQ Stock Market: Why Summit Therapeutics Stock Crushed the Market This Week